3 / 21
Page 26
Volume 2
Journal of Molecular Cancer
Cancer & Primary Healthcare 2019
May 20-21, 2019
Cancer Research & Oncology
Primary Healthcare and Medicare Summit
May 20-21, 2019 | Rome, Italy
25
th
Global Meet on
World Congress on
&
Plasma filtration (PF) effectively removes circulating pegylated liposomal doxorubicin
(pld) and modifies chemotherapy-related toxicity in metastatic ovarian cancer
Ondřej Kubeček
University Hospital in Hradec Králové, Czech Republic
Statement of the Problem:
Pegylated liposomal doxorubicin (PLD), a formulation of doxorubicin
hydrochloride encapsulated in polyethyleneglycol-coated liposomes, has proved its efficacy in the treatment
of ovarian cancer and other solid tumors. The major dose-limiting toxicities include hand-foot syndrome
(HFS) and mucositis. Thanks to the unique pharmacokinetic properties of PLD and the defective vasculature
of the tumor tissue, the peak PLD concentration in the tumor is attained considerably faster than in other
tissues in which toxic reactions occur. Interestingly, less than 5% of the administered dose is delivered to the
target tissue; hence, it is believed that the majority of the administered PLD has a limited therapeutic value
and is merely responsible for organ toxicity. Therefore, the extracorporeal removal of circulating PLD could
be a promising method to increase PLD tolerability while preserving its antitumor activity. This study seeks to
evaluate the safety and efficacy of PF and the related changes in chemotherapy-related toxicity.
Methodology & Theoretical Orientation:
Patients with platinum-resistant ovarian cancer were treated with
PLD 50 mg/m2 in one-hour IV infusion q4w, followed by plasma filtration (PF) performed at hours 44(46)-
47(49) post dose. Plasma PLD concentration was measured to assess the pharmacokinetic parameters and PF
efficacy. Treatment-related toxicity and the patients’ outcome were also evaluated.
Findings:
Fifteen patients were enrolled in this study and received a median of 3 (2-6) chemotherapy cycles. In
all, 53 PF cycles were evaluated. PF eliminated a median of 30.1% (12.7-64.6%) of the administered PLD dose.
Only one case of grade 3 HFS and grade 1 mucositis were documented.
Conclusion & Significance:
Plasma filtration represents a potent method in the removal of circulating PLD. It
is well tolerated and it seemingly reduces the incidence of hand-foot syndrome and mucositis.
Biography
Ondřej Kubeček is a graduate of Charles University, Faculty of Medicine in Hradec Králové, Czech Republic. He has been practicing
since 2012 as the medical oncologist at the Department of Oncology and Radiotherapy at the Hradec Králové University Hospital. He
focuses on the treatment of GI cancers, malignant melanoma, and ovarian cancer. In 2016, Kubeček worked as a research scholar at
the Department of Experimental Medicine and Pathology at Mayo Clinic, Rochester, USA. As a PhD student, he is currently working
on a research project dedicated to the use of extracorporeal elimination of pegylated liposomal doxorubicin to improve the treatment
tolerability in patients with ovarian cancer
okubec@gmail.comJ Mol Cancer, Volume 2